Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer similar to other high-grade neuroendocrine carcinomas

Human Pathology

Volumn 40, Issue 2, 2009, Pages 238-243

  Pryor, Jennifer G ^a   Simon, Rochelle A ^a   Bourne, Patricia A ^a   Spaulding, Betsy O ^a   Scott, Glynis A ^b   Xu, Haodong ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b AGILENT TECHNOLOGIES   (United States)

Author keywords

IMP 3; KOC; L523S; Merkel cell carcinoma; Neuroendocrine carcinoma

Indexed keywords

BIOLOGICAL MARKER; IMP 3 PROTEIN; L523S PROTEIN; MONOCLONAL ANTIBODY; RNA BINDING PROTEIN; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOMA; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MALE; MERKEL CELL TUMOR; METASTASIS; MITOSIS; NEUROENDOCRINE CARCINOMA; PROTEIN EXPRESSION; TARGET CELL; TUMOR BIOPSY; TUMOR CELL; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MERKEL CELL; CARCINOMA, NEUROENDOCRINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RNA-BINDING PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149121248     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.07.009     Document Type: Article

References (35)

1. Bichakjian C.K., Lowe L., Lao C.D., et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 110 (2007) 1-12
2. Miller R.W., and Rabkin C.S. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev 8 (1999) 153-158
3. Cervigon I., Gargallo A.B., Bahillo C., et al. Merkel cell carcinoma in a patient with chronic lymphocytic leukemia. Actas Dermosifiliogr 97 (2006) 264-266
4. Medina-Franco H., Urist M.M., Fiveash J., et al. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 8 (2001) 204-208
5. Penn I., and First M.R. Merke's cell carcinoma in organ recipients: report of 41 cases. Transplantation 68 (1999) 1717-1721
6. Buell J.F., Trofe J., Hanaway M.J., et al. Immunosuppression and Merkel cell cancer. Transplant Proc 34 (2002) 1780-1781
7. Robak E., Biernat W., Krykowski E., et al. Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab. Leukemia Lymph 46 (2005) 909-914
8. Takabayashi M., Sakai R., Sakamoto H., et al. Merkel cell carcinoma developing after antithymocyte globulin and cyclosporine therapy for aplastic anemia. Anticancer Drugs 14 (2003) 251-253
9. Dancey A.L., Rayatt S.S., Soon C., et al. Merkel cell carcinoma: a report of 34 cases and literature review. J Plast Reconstr Aesthet Surg 59 (2006) 1294-1299
10. Lunder E.J., and Stern R.S. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med 339 (1998) 1247-1248
11. Popp S., Waltering S., Herbst C., et al. UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 99 (2002) 352-360
12. Agelli M., and Clegg L.X. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 49 (2003) 832-841
13. Nicole C.H. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 89 (2005) 1-4
14. Swann M.H., and Yoon J. Merkel cell carcinoma. Semin Oncol 34 (2007) 51-56
15. Skelton H.G., Smith K.J., Hitchcock C.L., et al. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 37 (1997) 734-739
16. Moll R., Löwe A., Laufer J., et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 140 (1992) 427-447
17. Chan J.K., Suster S., Wenig B.M., et al. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol 21 (1997) 226-234
18. Hanly A.J., Elgart G.W., Jorda M., et al. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates Merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 27 (2000) 118-120
19. Abbasi A.N. Clinical features and management of Merkel cell carcinoma. J Pak Med Assoc 57 (2007) 368-371
20. Clark J.R., Veness M.J., Gilbert R., et al. Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary?. Head Neck 29 (2007) 249-257
21. Decker R.H., and Wilson L.D. Role of radiotherapy in the management of Merkel cell carcinoma of the skin. J Natl Compr Canc Netw 4 (2006) 713-718
22. Jabbour J., Cumming R., Scolyer R.A., et al. Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease-results from a review of 82 consecutive cases diagnosed between 1992 and 2004. Ann Surg Oncol 14 (2007) 1943-1952
23. Garneski K.M., and Nghiem P. Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol 57 (2007) 166-169
24. Poulsen M.G., Rischin D., Porter I., et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?. Int J Radiat Oncol Biol Phys 64 (2006) 114-119
25. In: Ries L.A.G., Young J.L., Keel G.E., et al. (Eds). SEER survival monograph: cancer survival among adults: US SEER program, 1988-2001, patient and tumor characteristics (2007), National Cancer Institute, Bethesda (Md) 251-262 [SEER Program, NIH Pub. No. 07-6215]
26. Xu H., Bourne P.A., Spaulding B.O., et al. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 38 (2007) 555-563
27. Simon R., Bourne P.A., Yang Q., et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol 38 (2007) 1178-1183
28. Nielsen J., Christiansen J., Lykke-Andersen J., et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19 (1999) 1262-1270
29. Liao B., Hu Y., Herrick D.J., et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280 (2005) 18517-18524
30. Müeller-Pillasch U.L., Wallrapp C., Micha A., et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14 (1997) 2729-2733
31. Hammer N.A., Hansen T.v.O., Byskov A.G., et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 130 (2005) 203-212
32. Gu L., Shigemasa K., and Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol 24 (2004) 671-678
33. Yantiss R.K., Woda B.A., Fanger G.R., et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 29 (2005) 188-195
34. Wang T., Fan L., Watanabe Y., et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 88 (2003) 887-894
35. Pryor J.G., Bourne P.A., Yang Q., et al. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 21 (2008) 431-437